GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Other Long-Term Liabilities

Heidelberg Pharma AG (XTER:HPHA) Other Long-Term Liabilities : €21.20 Mil (As of May. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Other Long-Term Liabilities?

Heidelberg Pharma AG's other long-term liabilities for the quarter that ended in May. 2024 was €21.20 Mil.

Heidelberg Pharma AG's quarterly other long-term liabilities declined from Nov. 2023 (€1.17 Mil) to Feb. 2024 (€-0.00 Mil) but then increased from Feb. 2024 (€-0.00 Mil) to May. 2024 (€21.20 Mil).

Heidelberg Pharma AG's annual other long-term liabilities increased from Nov. 2021 (€0.02 Mil) to Nov. 2022 (€5.90 Mil) but then declined from Nov. 2022 (€5.90 Mil) to Nov. 2023 (€1.17 Mil).

Heidelberg Pharma AG Other Long-Term Liabilities Historical Data

The historical data trend for Heidelberg Pharma AG's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Other Long-Term Liabilities Chart

Heidelberg Pharma AG Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Heidelberg Pharma AG Quarterly Data
Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Heidelberg Pharma AG Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Heidelberg Pharma AG Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Heidelberg Pharma AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Other Long-Term Liabilities
Comparable Companies
XTER:MDG1 FRA:D89 FRA:T5O0 OCSE:NOVO B REGN VRTX ASX:CSL XKRX:207940 ALNY XBRU:UCB XKRX:068270 MRNA XBRU:ARGX BGNE BNTX OCSE:GMAB BMRN UTHR INSM SRPT
Traded in Other Exchanges
HPHA:Germany
Address
Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Website
https://www.heidelberg-pharma.com
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
Executives
Prof. Dr. Andreas Pahl Board of Directors

Heidelberg Pharma AG Headlines

No Headlines